AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ETHOSUXIMIDE
5 registrations across 3 African markets— 2 active
Markets with ETHOSUXIMIDE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| ETHOSUXIMIDE MC PHARMA | 🇿🇦South Africa | MC Pharma (Pty) Ltd | active | Jan 2030 |
| CP- ETHOSUXIMIDE CAPSULE | 🇿🇼Zimbabwe | COSPHARM INVESTMENTS PVT LTD | active | Dec 2027 |
| ETHOSUXIMIDE | 🇿🇦South Africa | Pharmacare Limited û Woodmead | suspended | Jul 2024 |
| ZARONTIN 250MG CAPSULE CAPSULE | 🇲🇼Malawi | — | expired | Jun 1996 |
| ZARONTIN 250MG SYRUP SYRUP | 🇲🇼Malawi | — | expired | Jun 1996 |
ETHOSUXIMIDE in Africa — Regulatory Overview
ETHOSUXIMIDE is registered across 3 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Malawi, South Africa, Zimbabwe. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 2 (40%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.